HMC launches groundbreaking pharmacogenomics initiative
The Peninsula
Doha, Qatar: Hamad Medical Corporation (HMC), Qatar s leading provider of secondary and tertiary healthcare, is excited to unveil a revolutionary adva...
Doha, Qatar: Hamad Medical Corporation (HMC), Qatar's leading provider of secondary and tertiary healthcare, is excited to unveil a revolutionary advancement in Precision medicine through the clinical implementation of pharmacogenomics.
This pioneering initiative positions HMC as the first institution in Qatar and among a select few in the Middle East to incorporate pharmacogenomics into routine clinical practice.
Pharmacogenomics studies how genes affect an individual's response to medications.
It combines pharmacology and genomics to develop personalized drug therapies and considers each patient's unique genetic profile to enhance drug efficacy while minimizing adverse effects.